Brief Communications in 2022

ATX-101, a cell-penetrating protein targeting PCNA, can be safely administered as intravenous infusion in patients and shows clinical activity in a Phase 1 study

• Charlotte Rose Lemech
• Ganessan Kichenadasse
• Michael Millward

STAT5 confers lactogenic properties in breast tumorigenesis and restricts metastatic potential

• Meng Lin
• Amy T. Ku
• Yi Li

A proof of concept for targeting the PrP^C - Amyloid β peptide interaction in basal prostate cancer and mesenchymal colon cancer

• Sophie Mouillet-Richard
• Séverine Martin-Lannerée
• Pierre Laurent-Puig

Functional screening reveals HORMAD1-driven gene dependencies associated with translesion synthesis and replication stress tolerance

• Dalia Tarantino
• Callum Walker
• Andrew NJ Tutt

Physiological expression of PI3K H1047R mutation reveals its anti-metastatic potential in ErbB2-driven breast cancer

• Alexandra M. Simond
• Tung Bui
• William J. Muller

A novel HSP90 inhibitor SL-145 suppresses metastatic triple-negative breast cancer without triggering the heat shock response

• Ji Young Kim
• Tae-Min Cho
• Jae Hong Seo

Epigenetic regulation of EIF4A1 through DNA methylation and an oncogenic role of eIF4A1 through BRD2 signaling in prostate cancer

• Chao Wang
• Jonathan Leavenworth
• Runhua Liu

NFκB activation by hypoxic small extracellular vesicles drives oncogenic reprogramming in a breast cancer microenvironment

• Irene Bertolini
• Michela Perego
• Dario C. Altieri

The BCL-2 family member BOK promotes KRAS-driven lung cancer progression in a p53-dependent manner

• Anna-Lena Meinhardt
• Enkhtsetseg Munkhbaatar
• Philipp J. Jost

An mRNA expression-based signature for oncogene-induced replication-stress

• Sergi Guerrero Llobet
• Arkajyoti Bhattacharya
• Marcel A. T. M. van Vugt

Aminopyridine analogs selectively target metastatic pancreatic cancer

• Rana V. Smalling
• Matthew E. Bechard
• Oliver G. McDonald